Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Ovarian Neoplasms 7Breast Neoplasms 4Multiple Myeloma 2Stomach Neoplasms 1Sarcoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Ovarian Cancer 1

Interventions

Cyclophosphamide 30N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 21Prednisone 20Etoposide 20Vincristine 16Whole-Body Irradiation 15Doxorubicin 15fludarabine phosphate 14Peripheral Blood Stem Cell Transplantation 14romidepsin 13Mycophenolic Acid 12Lenalidomide 12Gemcitabine 12Cyclosporine 10Azacitidine 10Brentuximab Vedotin 9Bortezomib 9Alemtuzumab 8Dexamethasone 7Methotrexate 6Cytarabine 6Busulfan 6Carmustine 5pembrolizumab 4fludarabine 4Vorinostat 4Tacrolimus 4Rituximab 4Melphalan 4Ifosfamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, T-Cell, Peripheral × 1-dodecylpyridoxal × Clear all
NCT03952572 2019-05-16

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Peking University

Phase 3 Unknown
244 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡